Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Tax Provisions (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Tax Provisions for 4 consecutive years, with -$31000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 65.56% to -$31000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $497000.0, a 27.76% increase, with the full-year FY2025 number at $497000.0, up 43.64% from a year prior.
  • Tax Provisions was -$31000.0 for Q4 2025 at Rhythm Pharmaceuticals, down from $111000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $22.0 million in Q1 2021 to a low of -$9.0 million in Q3 2021.
  • A 4-year average of $755916.7 and a median of $95500.0 in 2025 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: plummeted 145.92% in 2024, then skyrocketed 137.0% in 2025.
  • Rhythm Pharmaceuticals' Tax Provisions stood at -$9.0 million in 2021, then skyrocketed by 102.18% to $196000.0 in 2023, then tumbled by 145.92% to -$90000.0 in 2024, then surged by 65.56% to -$31000.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Tax Provisions are -$31000.0 (Q4 2025), $111000.0 (Q3 2025), and $337000.0 (Q2 2025).